Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PCSK9 Inhibitor
SBC-115337 is a potent PCSK9 inhibitor, demonstrating an IC50 value of 0.5 μM. By targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), this compound plays a critical role in modulating cholesterol metabolism. SBC-115337 is suitable for research applications aimed at studying lipid metabolism, cardiovascular diseases, and the development of therapies for hypercholesterolemia. -
PCSK9 Inhibitor
PF-06815345 hydrochloride is a potent, orally active inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), demonstrating an IC50 of 13.4 μM. This compound effectively reduces PCSK9 levels in vivo in mouse models, making it a valuable tool for research into lipid metabolism and cardiovascular disease. Its role as a PCSK9 inhibitor positions it for studies aimed at exploring cholesterol regulation and related therapeutic interventions. -
PCSK9 Inhibitor
PF-06446846 is an orally active inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). This compound selectively targets PCSK9 translation by stalling the 80S ribosome near the codon region, effectively reducing PCSK9 levels. It has significant implications in research related to cholesterol metabolism and cardiovascular diseases, making it a valuable tool for investigations into lipid regulation and associated therapeutic strategies. -
PCSK9 Inhibitor
PF-06815345 is a potent and orally active inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), exhibiting an IC50 value of 13.4 μM. This compound has been shown to significantly reduce PCSK9 levels in vivo in mouse models. PF-06815345 serves as a valuable tool for studying cholesterol metabolism and the modulation of LDL receptor activity, making it relevant for research in cardiovascular diseases and lipid regulation. -
PCSK9 Inhibitor
7030B-C5 is a potent PCSK9 inhibitor with an IC50 of 1.61 μM. This compound effectively reduces plasma cholesterol and triglyceride levels in vivo, contributing to the attenuation of atherosclerosis progression. 7030B-C5 serves as a valuable tool in cardiovascular disease research, facilitating the exploration of lipid metabolism and associated therapeutic strategies. -
PCSK9 Inhibitor
Bezeparsen is a potent PCSK9 synthesis inhibitor that regulates LDL cholesterol levels by enhancing hepatic LDL receptor activity. It plays a critical role in lipid metabolism and is used in cardiovascular research to study cholesterol homeostasis and potential therapeutic interventions for hyperlipidemia. This compound is valuable for investigations focusing on the modulation of cholesterol levels and cardiovascular disease management. -
PCSK9 Inhibitor
PCSK9 modulator-2 is a potent inhibitor of PCSK9, exhibiting an EC50 value of 202 nM. PCSK9 plays a critical role in the regulation of low-density lipoprotein cholesterol (LDL-C) levels in the blood. This modulator presents valuable utility in research focused on hyperlipidemia and cholesterol metabolism, offering insights into potential therapeutic strategies for managing lipid disorders. -
PCSK9 Inhibitor
PCSK9-IN-16 is a potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting PCSK9, this compound plays a crucial role in regulating cholesterol levels, making it relevant for research into hypercholesterolemia and other cardiovascular diseases. It offers a valuable tool for studies focused on lipid metabolism and potential therapeutic interventions in lipid disorders. -
PCSK9 Inhibitor
SPC4061 is a potent PCSK9 inhibitor that utilizes an antisense nucleotide mechanism. By specifically targeting the locked nucleic acid (LNA) of PCSK9, it plays a crucial role in the study of hypercholesterolemia and associated metabolic disorders. This compound enables researchers to explore the regulation of cholesterol metabolism and related therapeutic approaches. -
PCSK9 Inhibitor
PCSK9 modulator-3 is a potent inhibitor of PCSK9, exhibiting an EC50 value of 2.46 nM. By targeting PCSK9, this compound facilitates the reduction of low-density lipoprotein cholesterol (LDL-C) levels. PCSK9 modulator-3 is valuable for research into hyperlipidemia and potential therapeutic strategies for managing cholesterol-related disorders. -
PCSK9 Inhibitor
PCSK9-IN-18 is a potent inhibitor of PCSK9, demonstrating a KD value of less than 200 nM. By targeting PCSK9, this compound plays a critical role in modulating LDL receptor levels and lipid metabolism. It is valuable for research in cardiovascular diseases and the development of therapies aimed at lowering cholesterol levels. -
PCSK9 Inhibitor
PCSK9-IN-22 is a potent orally active inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). This compound effectively disrupts the interaction between PCSK9 and low-density lipoprotein receptor (LDLR), leading to increased LDLR levels and enhanced clearance of LDL cholesterol. PCSK9-IN-22 is valuable for research applications related to cholesterol metabolism, cardiovascular disease, and lipid regulation. -
PCSK9 Inhibitor
PCSK9-IN-26 is a potent inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) with an IC50 value of less than 1 nM. This compound effectively modulates lipid metabolism by preventing PCSK9-mediated degradation of LDL receptors, thereby promoting cholesterol uptake. PCSK9-IN-26 is valuable for research applications focused on cardiovascular diseases and metabolic disorders related to cholesterol homeostasis. -
PCSK9 Inhibitor
PCSK9-IN-31 is a potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). This compound effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels in high cholesterol-fed rat models. It is valuable for research applications focused on cholesterol metabolism and cardiovascular disease. -
PCSK9 Inhibitor
PCSK9-IN-14 is a potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). By targeting PCSK9, this compound effectively enhances LDL receptor degradation and promotes lipid metabolism. It serves as a valuable tool for research into cholesterol metabolism and the development of therapies for hypercholesterolemia. -
PCSK9 Inhibitor
PCSK9-IN-17 is a selective inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), targeting the regulation of cholesterol metabolism. This compound has demonstrated efficacy in modulating LDL receptor levels, thereby enhancing lipid homeostasis. PCSK9-IN-17 is primarily utilized in research focused on cholesterol metabolism and cardiovascular disease mechanisms, providing valuable insights into therapeutic strategies for dyslipidemia and related disorders. -
PCSK9 Inhibitor
PCSK9-IN-24 is a potent inhibitor of PCSK9, a key regulator of LDL receptor degradation. By reducing PCSK9 levels, this compound facilitates increased LDL uptake by cells, making it valuable for investigations into cholesterol metabolism and atherosclerosis. Its application in research can enhance the understanding of lipid disorders and aid in the development of therapeutic strategies targeting cardiovascular diseases. -
PCSK9 Inhibitor
PCSK9 modulator-4 is a potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), exhibiting an EC50 value of 0.15 nM. By targeting PCSK9, this compound plays a crucial role in reducing low-density lipoprotein cholesterol (LDL-C) levels. PCSK9 modulator-4 is particularly relevant for research focused on hyperlipidemia and related cardiovascular diseases. -
PCSK9 Inhibitor
PCSK9-IN-15 is a potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), with a known dissociation constant (KD) of less than 200 nM. PCSK9 plays a critical role in cholesterol metabolism, primarily regulating low-density lipoprotein cholesterol (LDL-C) levels in the bloodstream. This compound is valuable for investigating cholesterol-lowering effects and the mechanisms underlying dyslipidemia. -
Ser/Thr Protease Inhibitor
PCSK9-IN-1 is a potent cyclic peptide inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) with a Ki value of 1.46 nM. This compound effectively inhibits the catalytic activity of PCSK9, leading to increased low-density lipoprotein receptor (LDLR) levels. PCSK9-IN-1 can be utilized in research focused on cholesterol metabolism, cardiovascular disease, and the development of therapeutics targeting dyslipidemia. -
PCSK9 Inhibitor
PCSK9-IN-20 is a potent PCSK9 inhibitor with an IC50 of 3.96 µM. This compound effectively reduces PCSK9 levels and upregulates LDL receptor (LDLR) expression in vitro. It serves as a valuable tool for research applications focused on cholesterol metabolism and cardiovascular disease mechanisms. -
cPLA2 Inhibitor
AACOCF3, or Arachidonyl trifluoromethyl ketone, is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2), exerting its effects through slow binding interactions. This compound is capable of blocking the production of both arachidonate and 12-hydroxyeicosatetraenoic acid in platelets stimulated by calcium ionophores. Additionally, AACOCF3 has been shown to inhibit glucose-induced insulin secretion from isolated rat islets, suggesting its potential utility in studying pathways related to cardiovascular disease and metabolic regulation. -
PLA2 Inhibitor
Pyrrophenone is a highly selective inhibitor of cytosolic phospholipase A2α (cPLA2α), exhibiting an IC50 value of 4.2 nM. This compound is valuable for research on phospholipid metabolism and inflammatory processes, as cPLA2α plays a critical role in the release of arachidonic acid and the production of inflammatory mediators. Pyrrophenone can be used to study the physiological effects of cPLA2α inhibition in various cellular and animal models. -
PGAM5 Inhibitor
LFHP-1c is a selective inhibitor of PGAM5, known for its neuroprotective properties in the context of brain ischemic stroke. This compound enhances the integrity of the blood-brain barrier by preventing ischemia-induced damage. LFHP-1c functions by binding to endothelial PGAM5, thereby inhibiting its phosphatase activity and disrupting its interaction with NRF2. It demonstrates protective effects both in vitro and in vivo, making it a valuable tool for research on ischemic conditions and related therapeutic strategies. -
N-SMase 2 Inhibitor
DPTIP is a selective inhibitor of neutral sphingomyelinase 2 (N-SMase 2), demonstrating a potent inhibitory activity with an IC50 of 30 nM. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for studying the biological roles of N-SMase 2 in various neurobiological processes. Its application in research includes investigating exosome biogenesis and sphingolipid metabolism, providing insights into cellular signaling pathways in neurological disorders. -
NAPE-PLD Inhibitor
LEI-401 is a selective inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD), exhibiting an IC50 of 27 nM. This CNS-active compound has been shown to modulate emotional behavior in mice, making it a valuable tool for research into neurochemistry and behavioral science. Its unique mechanism of action positions LEI-401 as a candidate for exploring therapeutic pathways in mood disorders and related conditions. -
Phospholipase Inhibitor
Bromoenol lactone is a selective and potent irreversible inhibitor of calcium-independent phospholipase A2 (iPLA2β), exhibiting an IC50 of approximately 7 μM. This compound effectively inhibits antigen-stimulated mast cell exocytosis without interfering with calcium influx. Bromoenol lactone is valuable for research applications aimed at understanding the roles of phospholipases in cellular processes and inflammatory responses. -
sPLA2 Inhibitor
Tris(2,4-di-tert-butylphenyl)phosphate is a potent inhibitor of secretory Phospholipase A2 (sPLA2), demonstrating significant anti-inflammatory activity. Isolated from the leaves of Vitex negundo L., this compound has been supported by molecular docking studies that confirm its inhibitory effects. It is particularly useful in research applications focused on inflammatory processes and lipid metabolism. -
PLC-γ Inhibitor
CCT129957 is a selective inhibitor of phospholipase C-γ (PLC-γ) with an IC50 of approximately 3 μM, demonstrating significant potency. This indole derivative effectively inhibits Ca2+ release in squamous carcinoma cells at a concentration of around 15 μM. CCT129957 is valuable for research applications targeting PLC-γ signaling pathways, providing insights into cellular function and disease mechanisms. -
Phospholipase Inhibitor
1-Naphthaleneacetic acid is an auxin that primarily acts as a phospholipase A2 (PLA2) inhibitor, exhibiting an IC50 of 13.16 μM. This compound is instrumental in promoting plant growth by modulating hormone levels and enhancing cell elongation. Additionally, its role in inhibiting PLA2 has made it a valuable tool in studying signaling pathways and inflammation in various biological systems. -
Phospholipase Inhibitor
MJ33 lithium salt is a competitive, reversible inhibitor targeting phospholipase A2 (PLA2). This compound specifically inhibits calcium-independent phospholipase A2 (iPLA2) activity of Prdx6, making it a valuable tool for researching phospholipid signaling pathways. MJ33 is utilized in studies focused on inflammation and cell signaling related to phospholipid metabolism. -
PTDSS1 Inhibitor
DS55980254 is an orally active inhibitor of phosphatidylserine synthase 1 (PTDSS1), effectively blocking the synthesis of intracellular phosphatidylserine. Inhibition of PTDSS1 disrupts the balance of cell membrane phospholipid components, which can subsequently activate B cell receptor (BCR) signaling pathways. This compound is valuable for research focused on phospholipid metabolism and its implications in B cell signaling and immune responses. -
SMS1 Inhibitor
SMS1-IN-1 is a potent sphingomyelin synthase 1 (SMS1) inhibitor with an IC50 of 2.1 μM. This compound demonstrates significant biological activity relevant to lipid metabolism and cellular signaling pathways. SMS1-IN-1 is primarily utilized in research focused on atherosclerosis, offering insights into its molecular mechanisms and potential therapeutic strategies. -
PLA2 Inhibitor
ONO-RS-082 is a selective inhibitor of phospholipase A2 (PLA2), demonstrating an IC50 of 1.0 μM. This compound uniquely lacks activity against phospholipase C (PLC), even at concentrations up to 100 μM. ONO-RS-082 is applicable for research involving the modulation of PLA2 activity and can facilitate studies related to inflammatory processes and cell membrane dynamics. -
PLD2 Inhibitor
VU0364739 is a selective inhibitor of phospholipase D2 (PLD2) with an IC50 of 22 nM. This compound has been shown to decrease cancer cell proliferation, making it a valuable tool for studying the role of PLD2 in tumor biology. Its application in cancer research allows for further exploration of the molecular mechanisms underlying cell growth and proliferation. -
sPLA2 Inhibitor
KH064 is a potent inhibitor of secretory phospholipase A2 (sPLA2), specifically targeting human nonpancreatic secretory PLA2 isoform IIa (hnpsPLA2-IIa) with an IC50 of 29 nM. This D-tyrosine derivative exhibits significant anti-inflammatory activity, making it suitable for research applications in inflammation and related disease models. Its oral bioavailability further enhances its potential for in vivo studies in pharmacological and toxicological research. -
ASM Inhibitor
ASM-IN-1 is a potent inhibitor of acid sphingomyelinase (ASM) with an IC50 value of 1.5 µM. It exhibits significant bioactivity by reducing lipid plaques in the aortic arch and aorta, as well as decreasing plasma ceramide concentration and oxidized low-density lipoprotein (Ox-LDL) levels. ASM-IN-1 demonstrates antiatherosclerotic and anti-inflammatory properties, making it valuable for research in cardiovascular diseases and lipid metabolism. -
Phospholipase A2 Inhibitor
PACOCF3 (Palmityltrifluoromethylketone) is a selective inhibitor of phospholipase A2, demonstrating an IC50 of 3.8 μM. This compound effectively modulates Ca2+ signaling within renal tubular cells, making it a valuable tool for studying phospholipase A2-related pathways and their implications in renal physiology and pathology. Researchers can utilize PACOCF3 to explore therapeutic interventions in conditions mediated by altered phospholipid metabolism. -
Lp-PLA2 Inhibitor
GSK2647544 is an orally available, selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This enzyme is a calcium-independent phospholipase A2 involved in proinflammatory processes, primarily secreted by monocyte-derived macrophages. GSK2647544 demonstrates potential for modulation of inflammatory pathways and is applicable in research focusing on cardiovascular diseases and inflammatory disorders. -
Serine Hydrolases Inhibitor
ABC47 is a potent inhibitor of serine hydrolases, specifically targeting ABHD4 and ABHD3, with IC50 values of 0.03 μM and 0.1 μM, respectively. This compound plays a significant role in research related to infantile neuronal ceroid lipofuscinosis, making it a valuable tool for studying the mechanisms and treatment of this neurodegenerative disorder. Its specificity and potency facilitate investigations into serine hydrolase functions and their implications in various biological processes. -
cPLA2 Inhibitor
Giripladib is an indole-based inhibitor of cytosolic phospholipase A2 (cPLA2). It demonstrates potent inhibitory activity against cPLA2, making it a valuable tool for investigating inflammatory processes. Giripladib is applicable in research focused on osteoarthritis and breast cancer, facilitating studies on the role of phospholipase A2 in these conditions. -
cPLA2α Inhibitor
CAY10502 is a potent inhibitor of calcium-dependent cytosolic phospholipase A2 α (cPLA2α), exhibiting an IC50 of 4.3 nM in isolated enzyme assays. This compound is valuable for research into retinopathy and inflammatory diseases, highlighting its potential role in modulating lipid metabolism and inflammation pathways. Its specificity and efficacy provide a useful tool for elucidating cPLA2α's involvement in various pathological processes. -
Lp-PLA2 Inhibitor
SB-435495 is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), exhibiting reversible and non-covalent binding with an IC50 of 0.06 nM. This compound demonstrates significant anti-inflammatory properties and is utilized in research related to cardiovascular diseases and atherosclerosis. Its oral bioavailability makes it a valuable tool for studying Lp-PLA2's role in various disease models. -
Phospholipase Inhibitor
1-Naphthaleneacetic acid potassium salt is a synthetic auxin that primarily inhibits phospholipase A2 (PLA2) with an IC50 of 13.16 μM. This compound is utilized in plant biology to promote growth and development, as well as in biochemical studies to explore the role of PLA2 in cellular processes. Its ability to modulate enzymatic activity makes it a valuable tool in both agricultural research and molecular biology investigations. -
sPLA2 Inhibitor
Varespladib sodium is a highly selective inhibitor of group IIA secretory phospholipase A2 (sPLA2), exhibiting an IC50 of 9 nM. This compound demonstrates significant inhibition of sPLA2 activity in serum from multiple species, including rat, rabbit, guinea pig, and human, with reported IC50 values of 8.1 nM, 5.0 nM, 3.2 nM, and 6.2 nM, respectively. Varespladib sodium is instrumental in studying inflammatory processes and lipid metabolism, making it valuable for research applications related to cardiovascular diseases and other sPLA2-mediated conditions. -
nSMase2 Inhibitor
nSMase2-IN-1 is an orally active inhibitor of Neutral sphingomyelinase 2 (nSMase2), exhibiting an IC50 value of 0.13 ± 0.06 μM. This compound demonstrates metabolic stability in liver microsomes and possesses a favorable brain-to-plasma ratio, making it suitable for studies involving central nervous system diseases. nSMase2-IN-1 is a valuable reagent for research applications focused on elucidating the role of sphingolipid metabolism in neurological disorders. -
Phospholipase Inhibitor
Aristolochic acid C is a potent inhibitor of phospholipase A2 (PLA2), a key enzyme involved in various inflammatory processes. This compound has demonstrated the ability to disrupt cortical microtubule arrays, thereby influencing cellular structure and root growth in Arabidopsis. Its applications extend to studies in plant biology and the investigation of signaling pathways mediated by phospholipase activity. -
sPLA2 Inhibitor
LY-311727 is a potent inhibitor of secretory non-pancreatic phospholipase A2 (sPLA2), demonstrating an IC50 of less than 1 μM for group IIA sPLA2. This compound functions by blocking the enzymatic activity of sPLA2, which plays a critical role in proinflammatory processes. LY-311727 is valuable for research focused on the modulation of inflammation and the investigation of sPLA2-related biological pathways. -
Phospholipase Inhibitor
(S)-Bromoenol lactone is an irreversible inhibitor targeting calcium-independent phospholipase A2β (iPLA2β). It effectively reduces the vasopressin-induced release of arachidonate from cultured rat aortic smooth muscle (A10) cells, demonstrating an IC50 of 2 µM. This compound serves as a valuable tool for studying phospholipase activity and its role in various cellular processes. -
Secreted Phospholipases A2 Inhibitor
N-Palmitoyl-l-leucine is an inhibitor of secreted phospholipases A2, targeting the hydrolysis of membrane phospholipids. This compound exhibits significant anti-inflammatory properties and is valuable in research applications related to inflammatory diseases and conditions associated with phospholipase activity. Its ability to modulate inflammatory responses makes it a useful tool for studying mechanisms of inflammation and potential therapeutic interventions.
